STIFEL

Morning Research Summary

Quick Look

daton Econ					
Symbol	Rating		Est.	Target Price	
	Prior	Current		Prior	Current
TARGET PRICE CHANGES					
BTE-TSX	Н	Н		C\$1.75	C\$2.00
<u>CYBN-</u> NEO	SB	SB		C\$5.00	C\$11.00
LUN-TSX	Н	Н		C\$12.50	C\$15.00
<u>WCP-</u> TSX	В	В		C\$7.50	C\$7.75
COMPANY UPDATES					
AEX- TSXV	В	В		C\$1.35	C\$1.35
AEM-TSX	В	В		C\$115.75 C\$115.75	
<u>CFW-</u> TSX	Н	Н		C\$4.00	C\$4.00
DIV-TSX	В	В		C\$2.85	C\$2.85
ERO-TSX	В	В		C\$30.00	C\$30.00
<u>LPS-</u> TSXV	В	В		C\$1.50	
PSI-TSX	Н	Н		C\$9.75	C\$9.75
<u>YRI-TSX</u>	В	В		C\$10.00	C\$10.00

INDUSTRY UPDATES

Canada - Energy Infrastructure

Canada - Energy Infrastructure - Energy Infrastructure Estimates

Canada - Oil & Gas

Canada - Oil & Gas - Oil & Gas Producer Estimates at Futures Pricing

Canada - Oilfield Services

Canada - Oilfield Services - Oilfield Services Estimates

Morning Meeting Highlights

Agnico Eagle Mines (AEM-TSX, C\$78.07, Buy; Target C\$115.75) - AEM posts an operating beat on record quarterly production - Ingrid Rico - Agnico Eagle released Q1 results which were a beat driven by stronger that expected production and better costs. Adj EPS of \$0.67 beat our estimate of \$0.57 and consensus of \$0.60. Pre-WC operating CFPS came in at \$1.42, in line with consensus but above our \$1.29. AEM generated FCF of \$175m, ahead of our \$136m. Production set a new quarterly record at 517koz (including production from Hope Bay), higher than our ~505k oz estimate. Total cash cost / AISC of \$734 / \$1,007/oz came in ~\$25/oz lower than our model. While peers have shown production lower QoQ, AEM started off the year with a sequential increase in production of 3% (or flat if we excluded production from Hope Bay). Amaruq and Meliadine stood out and drove the outperformance against our numbers. Construction continues for Malartic UG with promising step-out drilling results from East Gouldie. FY 2021 guidance was maintained.

Baytex Energy (BTE-TSX, C\$1.50, Hold; Target C\$2.00) - Baytex Surprises with Strong FFO in 1Q21, Increased 2021 Plans, Exciting Clearwater Test - Cody Kwong - Baytex's 1Q21 results were chock-full of exciting data points, led by posting a FFO figure that was 17% higher than consensus estimates. The Company also took the time to outline a 5-year plan (which included elevated 2021 guidance) that carried a headline figure of \$1.0 billion of cumulative FCF (at flat US\$55/bbl oil). The operational update was highlighted by a new Clearwater well, on a new 60 section parcel of land, that generated a solid IP30 rate of 175 bbl/d (2 legged well). Based on our forward outlook moving higher and some exciting catalysts on the come for Baytex, we are increasing our target price to \$2.00/sh.

Cybin Inc. (CYBN-NEO, C\$2.22, Speculative Buy; Target C\$11.00) - CYBN is a true multi-molecule company that's not being reflected in its valuation - Andrew **Partheniou** - POSITIVE — CYBN has been progressing rapidly along its path of developing a pipeline of novel psychedelic molecules, transforming the company from a single molecule strategy to a more diversified one with stronger IP opportunities. CYB003, a novel 2nd generation tryptamine that is designed for a shorter, more scalable duration of action, has already undergone proof-of-concept studies. In addition, the company is targeting Alcohol Use Disorder, a relapsing disease with high unmet needs, a large addressable market and low competition. With CMPS recently providing a goalpost for valuation, we believe CYBN's shares have a direct pathway for over ~3.5x upside near term as neither its primary candidate nor its first novel candidate—expected to enter clinical trials in 2021—is fully accounted for in its valuation, offering investors with an attractive entry point. Hence, we increase our target to \$11 from \$5 to reflect CYB003 and its strong potential to create shareholder value.

Ero Copper (ERO-TSX, C\$24.78, Buy; Target C\$30.00) - Greenfields discoveries represent a proof of concept for future discovery - **Ian Parkinson** - ERO's quarterly exploration update hit the wire this morning. We are most excited about two aspects, 1) Near mine Vermehlos 'grade bank' continually being added at depth, and 2) Regional exploration success at the newly discovered Terra do Sal System & C4 System. The discoveries represent a proof of concept for ERO's exploration process employed across the MCSA land package. They also provide good margin rock to maximize mill throughput.

Pason Systems (PSI-TSX, C\$9.42, Hold; Target C\$9.75) - In-line 1Q21 results - Cole Pereira - Pason reported 1Q21 results that were largely in line with Stifel and consensus estimates. Revenue of was \$43 mm, in line with Stifel's \$42 mm and the Street at \$41 mm, while EBITDAS of \$13 mm matched both our estimate and consensus. The company did not repurchase any shares in the quarter, but

Stifel does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

All relevant disclosures and certifications appear on pages 4 - 6 of this report.

did reaffirm its 2021e capital plan of \$15 mm. We expect the stock to trade in line tomorrow.

Other Focus Items Today

GMP

AEX Gold Inc. (AEX-TSXV, C\$0.46, Buy; Target C\$1.35) - Undertaking strategic review of Nalunaq strategy, shifting to exploration for 2021 season - <u>Stephen Soock</u> - Following the 1-year delay in the start of construction, AEX is conducting a strategic review of its development plan for Nalunaq. The company will complete an internal Feasibility-level study, aiming to de-risk the project, enter into a fixed price construction agreement and secure alternative (non-equity) financing. For the 2021 field season, AEX is pivoting to exploration, planning a 20-30,000m infill drill program at Nalunaq, building an all-year construction/exploration camp and conducting regional exploration on its large, multi-element prospective land package across southern Greenland. The company expects to spend C\$10m on site early work/exploration/project evaluation, C\$10m on receipt of long lead time items and C \$2m on regional exploration (AEX currently has C\$54m in cash).

Calfrac Well Services (CFW-TSX, C\$3.50, Hold; Target C\$4.00) - 1Q21 results update - **Cole Pereira** - CFW reported 1Q21 results slightly behind Stifel and consensus estimates with EBITDAS of \$12 mm behind our estimate of \$13 mm and the Street at \$14 mm. Our estimates are largely unchanged with this update, as are our Hold rating and \$4.00/sh target price. We continue to take a cautious view on CFW given its negative FCF profile, dilution from its restructuring, and potential legal risk. The stock also screens expensively at 5.3x 2022e EV/EBITDAS vs. both TCW and STEP at 4.6x.

Diversified Royalty Corp. (DIV-TSX, C\$2.49, Buy; Target C\$2.85) - DIV reports in-line Q1/21 operating results - Anoop Prihar - DIV reported preliminary Q1/21 operating metrics for its portfolio partners, which were essentially in line with our expectations. For Q1/21, we expect DIV will generate revenue of \$8.7mm, normalized EBITDA of \$8.0mm and DCPS of \$0.05 (107% payout ratio). Our FY21 and FY22 DCPS estimates of \$0.21 (96% payout ratio) and \$0.23 (88% payout ratio) respectively remain unchanged. Our target price of \$2.85/sh is derived by applying a 7% target yield to current distribution of \$0.20/sh. We continue to rate DIV a BUY.

Legend Power Systems Inc. (LPS-TSXV, C\$0.83, Buy; Target C\$1.50) - A new ESCO partnership and subsequent Insights engagement - Ian Gillies - LPS has announced a partnership with a second energy service company (ESCO) that is in the Fortune 500. Recall, the U.S. ESCO market is US\$10-15 bn per annum. This is an important announcement because 1) it provides LPS with a new ESCO sales channel which will help it meet our revenue forecasts; 2) creates a new sales vertical for helping property managers with acquisition due diligence, which would allow for SmartGATE installs after closing; and 3) proves the prior ESCO relationship was not a one-off. This is a positive announcement.

Lundin Mining (LUN-TSX, C\$15.80, Hold; Target C\$15.00) - 1Q21 misses street expectations; operations lag on mine sequencing and weather challenges - lan Parkinson - LUN hit our 1Q21 financials estimates but missed the street's expectations. Clean EPS of \$0.20/sh in line with our estimate of \$0.19/sh but behind consensus at \$0.24/sh, CFPS xWC of \$0.38/sh was closer to expectations, slightly off our estimate of \$0.39/sh and consensus at \$0.40/sh. The delta was driven by softer production (Attributable copper production of 50.5kt behind our estimate of 60.1kt Cu and consensus at 59.1kt Cu) in the quarter. Lower production at Candelaria, Chapada, and Neves-Corvo was all grade driven.

Whitecap Resources (WCP-TSX, C\$5.43, Buy; Target C\$7.75) - Busy 1Q21 Yields Better than Expected Operational and Financial Performance - <u>Cody Kwong</u> -Whitecap's 1Q21 was busy with the closing of the NAL Resources and TORC Oil & Gas transactions, along with carrying out its largest quarterly capital program slated for 2021. With all these moving parts we were impressed with production and cash flow figures that came in ahead of expectations while its capital investments were more efficient than anticipated.

Yamana Gold (YRI-TSX, C\$5.63, Buy; Target C\$10.00) - Yamana reports in-line Q1 results, provides update on growth projects - Ingrid Rico - Yamana reported



Q1 operating and financial results with production and cost broadly in line with our expectations for the quarter. CFPS of \$0.19 was slightly ahead of our expectations, but marginally below consensus; EPS of \$0.07 was in line. Production of 232k GEOs was in line and results are consistent with the expectation of back-half loaded production - anticipating sequential production increases in the remaining quarters. The company provided updates for construction and exploration at Odyssey, progress on the Jacobina Phase 2 expansion, and MARA study optimization work.



Note: Prices are as of the close of April 29, 2021, unless otherwise noted.

Important Disclosures and Certifications

The authors of this document certify that their respective views expressed in this research report accurately reflect their respective personal views about the subject securities or issuers; and, the authors of this document certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this research report.

Our European Policy for Managing Research Conflicts of Interest is available at www.stifel.com/institutional/ImportantDisclosures.

For applicable current disclosures for all covered companies please visit the Research Page at www.stifel.com or write to the Stifel Research Department at the following address.

Stifel Research Department

Stifel Nicolaus Canada Inc.

145 King Street West, Suite 300

Toronto, Ontario M5H1J8

The equity research analyst(s) responsible for the preparation of this report receive(s) compensation based on various factors, including Stifel's overall revenue, which includes investment banking revenue.

Investment Rating System

Our investment rating system is defined as follows:

Buy - We expect a total return of greater than 10% over the next 12 months with total return equal to the percentage price change plus dividend yield.

Speculative Buy¹ - We expect a total return of greater than 30% over the next 12 months, with total return equal to the percentage price change plus dividend yield, accompanied by substantially higher than normal risk including the possibility of a binary outcome.

Hold - We expect a total return between -5% and 10% over the next 12 months with total return equal to the percentage price change plus dividend yield.

Sell - We expect a total return below -5% over the next 12 months with total return equal to the percentage price change plus dividend yield.

Occasionally, we use the ancillary rating of **Suspended (SU)** to indicate a long-term suspension in rating and/or target price, and/or coverage due to applicable regulations or Stifel policies. Alternatively, **Suspended** may indicate the analyst is unable to determine a "reasonable basis" for rating/ target price or estimates due to lack of publicly available information or the inability to quantify the publicly available information provided by the company and it is unknown when the outlook will be clarified. **Suspended** may also be used when an analyst has left the firm.

¹ This rating is only utilised by Stifel Canada.

Of the securities we rate, 56% are rated Buy, 1% are rated Speculative Buy, 28% are rated Hold, 2% are rated Sell and 13% are rated Suspended.

Within the last 12 months, Stifel or an affiliate has provided investment banking services for 24%, 7%, 0%, 8% of the companies whose shares are rated Buy (includes Speculative Buy), Hold, Sell, and Suspended respectively.

Within the last 12 months, Stifel or an affiliate has provided material services for 41%, 73%, 21%, 13%, 12%, of the companies whose shares are rated Buy, Speculative Buy, Hold, Sell and Suspended respectively.

Additional Disclosures

The IHS data included in this report is supplied under license by IHS, for the internal use of Stifel, Nicolaus & Company's clients. IHS has not been involved with the creation of this report and shall not be liable for any errors or omissions or any loss incurred by reliance on any IHS data.

Please visit the Research Page at www.stifel.com for the current research disclosures and respective target price methodology applicable to the companies mentioned in this publication that are within Stifel Canada's coverage universe. For a discussion of risks to target price including basis of valuation or methodology, please see our stand-alone company reports and notes for all stocks.

The information contained herein has been prepared from sources believed to be reliable but is not guaranteed by us and is not a complete summary or statement of all available data, nor is it considered an offer to buy or sell any securities referred to herein. Opinions expressed are as of the date of this publication and are subject to change without notice. These opinions do not constitute a personal recommendation and do not take into account the particular investment objectives, financial situation or needs of individual investors. Employees of Stifel, or its affiliates may, at times, release written or oral commentary, technical analysis or trading strategies that differ from the opinions expressed within. Stifel or any of its affiliates may have positions in the securities mentioned and may make purchases or sales of such securities from time to time in the open market or otherwise and may sell to or buy from customers such securities on a principal basis; such transactions may be contrary to recommendations in this report. Past performance should not and cannot be viewed as an indicator of future performance. Unless otherwise noted, the financial instruments mentioned in this report are priced as of market close on the previous trading day and presumed performance is calculated always over the next 12 months.

As a multi-disciplined financial services firm, Stifel regularly seeks investment banking assignments and compensation from issuers for services including, but not limited to, acting as an underwriter in an offering or financial advisor in a merger or acquisition, or serving as a placement agent in private transactions.



Affiliate Disclosures

This report has been prepared by Stifel Nicolaus Canada Incorporated. ("**Stifel Canada**"), which is authorized and regulated by the Investment Industry Regulatory Organization of Canada ("**IIROC**"), and also trades under the names "**Stifel GMP**" and/or "**Stifel FirstEnergy**". All relevant disclosures required by regulatory rules (including IIROC) and Stifel Canada's recommendation statistics and research dissemination policies can be obtained at www.Stifel.com/Research or by calling Stifel Canada's Compliance Department. Stifel Canada will provide, upon request, a statement of its financial condition and a list of the names of its Directors and senior officers.

References to "**Stifel**" (collectively "Stifel") refer to SFC and other associated affiliated subsidiaries including (i) Stifel, Nicolaus & Company, Incorporated ("**SNC**"); (ii) Keefe, Bruyette & Woods, Incorporated ("**KBWI**"), which are both U.S. broker-dealers registered with the United States Securities and Exchange Commission ("**SEC**") and members of the Financial Industry National Regulatory Authority ("**FINRA**"), respectively; (iii) Stifel Nicolaus Canada, Incorporated. ("**Stifel Canada**"), which is authorised and regulated by Investment Industry Regulatory Organization of Canada ("**IIROC**"), and also trades under the names "**Stifel GMP**" and/or "**Stifel FirstEnergy**"; (iv) Stifel Nicolaus Europe Limited ("**SNEL**"), which is authorised and regulated by the Financial Conduct Authority ("**FCA**") (FRN 190412) and is a member of the London Stock Exchange and also trades under the name Keefe, Bruyette & Woods Europe ("**KBW Europe**"); and (v) Stifel Europe Bank AG ("**SEBA**"), which is regulated by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht; "BaFin") and is a member of Deutsche Boerse and SIX Swiss Exchange and (vi) Stifel Schweiz AG ("**STSA**"), which is representative of SEBA in Switzerland and regulated by the Eidgenössische Finanzmarktaufsicht ("**FINMA**"). SNEL, SEBA and STSA are collectively referred to as Stifel Europe.

Registration of non-US Analysts: Any non-US research analyst employed by Stifel contributing to this report is not registered/qualified as a research analyst with FINRA and is not an associated person of the US broker-dealer and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account.

Global Research Notes: Stifel Global Research (Cross-Border Research) notes are intended for use only by Institutional or Professional Clients. Research analysts contributing content to these reports are subject to different regulatory requirements based on the jurisdiction in which they operate. Clients seeking additional information should contact the Stifel entity through which they conduct business.

SEBA & STSA Sponsored Research: At SEBA & STSA, analysts may produce issuer paid research ('sponsored research'). This research is produced by analysts in accordance with local regulatory requirements relating to such research. In certain jurisdictions, this issuer paid research may be deemed to be independent research albeit not produced to the same conflicts of interest standards required by all jurisdictions for independent research. Where research has been paid for by an issuer, this will be clearly labelled. Please see our European Policy for Managing Research Conflicts of Interest for additional information.

Country Specific and Jurisdictional Disclosures

United States: Research produced and distributed by Stifel Canada is distributed by Stifel Canada to "Major US Institutional Investors" as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended. SNC may also distribute research prepared by Stifel Canada directly to US clients, including US clients that are not Major US Institutional Investors. In these instances, SNC accepts responsibility for the content. Stifel Canada is a non-US broker-dealer and accordingly, any transaction by a US client in the securities discussed in the document must be effected by SNC. US clients wishing to place an order should contact their SNC representative.

UK: This report is distributed in the UK by SNEL, which is authorised and regulated by the Financial Conduct Authority (FCA). In these instances, SNEL accepts responsibility for the content. Research produced by Stifel Europe is not intended for use by and should not be made available to retail clients as defined by the FCA.

European Economic Area (EEA): This report is distributed in the EEA by SEBA, which is authorized and regulated by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht; "BaFin"). In these instances, SEBA accepts responsibility for the content. Research produced by Stifel Europe is not intended for use by and should not be made available to retail clients as defined under MiFID II.

The complete preceding 12-month recommendations history related to recommendation(s) in this research report is available at https:// stifel2.bluematrix.com/sellside/MAR.action

Australia: Research produced by Stifel is distributed by SNEL under the Australian Securities and Investments Commission ("ASIC") Class Order [CO 03/1099] exemption from the requirement to hold an Australian Financial Services Licence ("AFSL"). This research may only be distributed to a "Wholesale Client" within the meaning of section 761G of the Corporations Act 2001 (Cth).

Brunei: This document has not been delivered to, registered with or approved by the Brunei Darussalam Registrar of Companies, Registrar of International Business Companies, the Brunei Darussalam Ministry of Finance or the Autoriti Monetari Brunei Darussalam. This document and the information contained within will not be registered with any relevant Brunei Authorities under the relevant securities laws of Brunei Darussalam. The interests in the document have not been and will not be offered, transferred, delivered or sold in or from any part of Brunei Darussalam. This document and the information contained within is strictly private and confidential and is being distributed to a limited number of accredited investors, expert investors and institutional investors under the Securities Markets Order, 2013 ("Relevant Persons") upon their request and confirmation that they fully understand that neither the document nor the information contained within have been approved or licensed by or registered with the Brunei Darussalam Registrar of Companies, Registrar of International Business Companies, the Brunei Darussalam Ministry of Finance, the Autoriti Monetari Brunei Darussalam or any other relevant governmental agencies within Brunei Darussalam. This document and the information contained within must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which the document or information contained within is only available to, and will be engaged in only with Relevant Persons.



Canadian Distribution: Stifel Canada is a member of IIROC and a participant of the TSX, and TSX Venture Exchange. 145 King Street West, Suite 300 Toronto, Ontario M5H 1J8 Tel: (416) 367-8600.

Republic of South Africa: Research produced by Stifel is distributed by SNEL to "Clients" as defined in FSCA FAIS Notice 20 of 2018 (the "FAIS Notice") issued by the Financial Services Conduct Authority. Research distributed by SNEL is pursuant to an exemption from the licensing requirements under Section 7(1) of the Financial Advisory and Intermediary Services Act, 2002.

In jurisdictions where Stifel is not already licensed or registered to trade securities, transactions will only be affected in accordance with local securities legislation which will vary from jurisdiction to jurisdiction and may require that a transaction is carried out in accordance with applicable exemptions from registration and licensing requirements. Non-US customers wishing to effect transactions should contact a representative of the Stifel entity in their regional jurisdiction except where governing law permits otherwise. US customers wishing to effect transactions should contact their US salesperson.

The securities discussed in this report may not be available for sale in all jurisdictions and may have adverse tax implications for investors. Clients are advised to speak with their legal or tax advisor prior to making an investment decision.

The recommendation contained in this report was produced at 30 April 2021 07:16EDT and disseminated at 30 April 2021 07:16EDT.

Additional Information Is Available Upon Request

© 2021 Stifel Canada. This report is produced for the use of Stifel Canada customers and may not be reproduced, re-distributed or passed to any other person or published in whole or in part for any purpose without the prior consent of Stifel Canada. Stifel Nicolaus Canada Inc., 145 King Street West, Suite 300, Toronto, Ontario M5H 1J8.